Indivior PLC (DE:E7P)
NASDAQ:E7P
E7P Stock Chart & Stats
€27.60
--
Market closed
€27.60
--
Day’s Range― - ―
52-Week Range€11.50 - €34.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)24.00
Market Cap
€3.95B
Enterprise Value€4.83B
Total Cash (Recent Filing)€175.00M
Total Debt (Recent Filing)€509.00M
Price to Earnings (P/E)18.7
Beta0.03
Next Earnings
Jul 30, 2026EPS Estimate
0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.01
Shares Outstanding121,922,060
10 Day Avg. Volume13
30 Day Avg. Volume24
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-45.77
Price to Sales (P/S)3.62
P/FCF Ratio-48.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€46.09Price Target Upside66.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)3.01
Revenue Forecast (FY)€1.06B
Bulls Say, Bears Say
Bulls Say
SUBLOCADE Commercial MomentumSUBLOCADE's strong and recurring monthly injection model demonstrates durable patient adoption and expanding prescriber engagement. Sustained unit growth and record new patient starts support predictable, sticky revenue streams and reinforce the company’s core commercial franchise as a long‑term earnings driver.
Margin & EBITDA Expansion With Raised GuidanceMaterial margin expansion and upgraded EBITDA guidance reflect operating leverage from product mix, cost reductions and scale. Higher sustained margins improve cash generation potential, fund capital allocation choices, and increase resilience to price and gross‑to‑net pressures over the medium term.
Debt Refinancing And Proactive Capital ActionsRefinancing high‑cost bank debt with low‑coupon convertibles materially reduces interest expense and covenant pressure, improving free‑cash‑flow prospects. Concurrent buybacks and retained buyback capacity signal disciplined capital allocation and greater balance sheet flexibility going forward.
Bears Say
Negative Shareholders' EquityPersistently negative equity is a structural balance‑sheet weakness that limits financial flexibility, complicates equity‑based metrics and could constrain strategic options. It increases reliance on debt or hybrids for growth funding and can raise stakeholder scrutiny despite low headline leverage.
Weak Operating Cash Flow (TTM)Negative cash conversion despite reported profitability indicates working‑capital drags or noncash earnings items that persistently reduce liquidity. This undermines the company’s ability to self‑fund commercial expansion, R&D or buybacks without recurring access to external financing.
Pipeline Setbacks And R&D DisruptionLosing internal advancement of two development programs and reorganizing R&D reduces future product diversification and increases dependence on SUBLOCADE. A thinner pipeline and leadership changes heighten long‑term growth risk and make the company more exposed to single‑product and competitive threats.
Indivior News
E7P FAQ
What was Indivior PLC’s price range in the past 12 months?
Indivior PLC lowest stock price was €11.50 and its highest was €34.00 in the past 12 months.
What is Indivior PLC’s market cap?
Indivior PLC’s market cap is €3.95B.
When is Indivior PLC’s upcoming earnings report date?
Indivior PLC’s upcoming earnings report date is Jul 30, 2026 which is in 50 days.
How were Indivior PLC’s earnings last quarter?
Indivior PLC released its earnings results on Apr 30, 2026. The company reported €0.833 earnings per share for the quarter, beating the consensus estimate of €0.573 by €0.26.
Is Indivior PLC overvalued?
According to Wall Street analysts Indivior PLC’s price is currently Undervalued.
Does Indivior PLC pay dividends?
Indivior PLC does not currently pay dividends.
What is Indivior PLC’s EPS estimate?
Indivior PLC’s EPS estimate is 0.76.
How many shares outstanding does Indivior PLC have?
Indivior PLC has 121,922,060 shares outstanding.
What happened to Indivior PLC’s price movement after its last earnings report?
Indivior PLC reported an EPS of €0.833 in its last earnings report, beating expectations of €0.573. Following the earnings report the stock price went up 5.442%.
Which hedge fund is a major shareholder of Indivior PLC?
Currently, no hedge funds are holding shares in DE:E7P
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Indivior Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€46.09 (66.97% Upside)
€46.09 (66.97% Upside)
Blogger Sentiment
Bullish
DE:E7P Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth €27.1K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
176.78%
12-Months-Change
Fundamentals
Return on Equity
-142.01%
Trailing 12-Months
Asset Growth
-12.95%
Trailing 12-Months
Company Description
Indivior PLC
Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence. Its product lineup features key pharmaceuticals such as Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company organizes its business into several geographical regions: the United States, the United Kingdom, and the broader international market. Established on September 26, 2014, its corporate headquarters are located in North Chesterfield, Virginia.
E7P Company Deck
E7P Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized strong commercial execution and substantial financial improvement driven by SUBLOCADE (double-digit revenue growth, 20% dispense unit growth, record adjusted EBITDA up 112% and raised 2026 guidance). It also announced disciplined capital actions that improve the balance sheet and return capital to shareholders. Offsetting these positives were setbacks in early-stage R&D (INDV-6001 and INDV-2000 not advancing internally), expected gross-to-net pressure for 2026, and ongoing reliance on SUBLOCADE for growth. On balance, the favorable commercial and financial momentum and upgraded guidance materially outweigh the program setbacks and known headwinds.View all DE:E7P earnings summariesE7P Stock 12 Month Forecast
Average Price Target
€46.09
▲(66.97% Upside)
Technical Analysis
Neurocrine
―
Supernus Pharmaceuticals
―
Teva Pharmaceutical
―
Collegium Pharmaceutical
―
Amneal Pharmaceuticals
―
Options Prices
Currently, No data available
---